Because I think that's what the attention that we are seeing right now is also giving
Hyattsville, MD: National Center for Health Statistics (2021)
Ohyama M, Shimizu A, Tanaka K, Amagai M (2010) Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata
The closest safety dataset is the Increlex (mecasermin) clinical program , which followed 71 pediatric patients with severe primary IGFD on twice-daily SubQ rhIGF-1 for a mean of 3.9 years (some patients up to 11.5 years)
Funny how at home, it's normal
Chart: GLP-1 search interest, via Google Trends